Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Average PT from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.33.

FULC has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Fulcrum Therapeutics Stock Up 2.4 %

Shares of FULC opened at $3.91 on Monday. Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70. The stock has a market cap of $210.91 million, a P/E ratio of -12.61 and a beta of 2.03. The business’s 50 day moving average price is $4.24 and its 200-day moving average price is $5.16.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors have recently bought and sold shares of FULC. Bank of New York Mellon Corp boosted its position in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock worth $667,000 after acquiring an additional 3,126 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock valued at $118,000 after purchasing an additional 6,926 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Fulcrum Therapeutics during the second quarter valued at about $82,000. Finally, Geode Capital Management LLC increased its holdings in shares of Fulcrum Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after purchasing an additional 13,485 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.